Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those emerging from more traditional…
Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those emerging from more traditional…
Ownership and Inventorship Ambiguity Introduction In Part I of this series, we introduced the idea that drug candidates emerging from artificial intelligence may have to be valued differently than those…
In America, we are adept at electing clowns and charlatans, and then ignoring or not bothering to understand what they are saying or doing. I blame this on our addictions…
A Five-Part Series on AI Drug Discovery Valuation Challenges Introduction I have no idea. That was my brilliant, insightful, memorable, put this on a t-shirt answer to the question posed…